Thomas W. Flaig - Concepedia

Author

Thomas W. Flaig

Also Known As

Adam Warren, Droller, Michael J., Flaig, T.W., Ralph Hauke, T W Flaig, T. Flaig, T. W. Flaig, T.W. Flaig, Thomas Flaig, Thomas W Flaig

390

Publications

22.9K

Citations

H-Index

Concepts

All Affiliations

University of Colorado Denver University of Colorado Cancer Center Memorial Sloan Kettering Cancer Center University of Colorado Anschutz Medical Campus Astellas Pharma (United States)

About

Thomas W. Flaig is an author at University of Colorado Denver specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	63	4.9K
2	Health Sciences	11	11	450
3	Engineering	3	3	113
4	Public Health	2	2	75
5	Nursing	1	1	17

Thomas W. Flaig

111

Publications

20.9K

Citations

H-Index

Page 1

	Year	Citations
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy Howard I. Scher, Karim Fizazi, Fred Saad, New England Journal of Medicine	2012	4.5K
Abiraterone and Increased Survival in Metastatic Prostate Cancer Johann S. de Bono, Christopher J. Logothetis, Arturo Molina, New England Journal of Medicine	2011	4.3K
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy Charles J. Ryan, Matthew R. Smith, Johann S. de Bono, New England Journal of Medicine	2012	2.8K
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study Charles J. Ryan, Matthew R. Smith, Karim Fizazi, The Lancet Oncology UrologyOncologyPrednisone Versus PlaceboAbiraterone AcetateClinical Trials	2015	1.3K
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology Thomas W. Flaig, Philippe E. Spiess, Neeraj Agarwal, Journal of the National Comprehensive Cancer Network	2020	619
Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma Robert J. Motzer, Carlos H. Barrios, Tae Min Kim, Journal of Clinical Oncology	2014	426
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients Thomas W. Flaig, Daniel L. Gustafson, Lih‐Jen Su, Investigational New Drugs UrologyOncologyMedicineProstate Cancer PatientsPharmacokinetic Study	2006	314
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma Jonathan E. Rosenberg, Srikala S. Sridhar, Jingsong Zhang, Journal of Clinical Oncology	2020	311
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022 Thomas W. Flaig, Philippe E. Spiess, Michael Abern, Journal of the National Comprehensive Cancer Network	2022	289
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Journal of the National Comprehensive Cancer Network Urological ResearchSurgical OncologyUrologyUrologic Cancer EpidemiologyGenitourinary Cancer	2017	276

Page 1